Biogen Scraps Two Alzheimer Drug Trials, Wipes $18 Billion From Market Value

[Fractality]

Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer’s disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and blow to Biogen, which lost more than $18 billion of its value on Thursday.

Experts had seen aducanumab as one of the last true tests of the hypothesis that removing sticky deposits of amyloid from the brain of patients in earlier stages of the lethal disease could stave off its ravages, which include loss of memory and the ability to care for oneself.

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value | Reuters

 

[Soren]

Seems like the nail in the coffin of the amyloid theory.